ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available Worldwide
December 11, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Dec. 11, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of Tru Niagen® Pro 500, the largest daily serving of its patented nicotinamide riboside (NR,...
ChromaDex and Matakana Announce Expanded Retail Partnership in Australia & New Zealand
December 05, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Dec. 05, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its partnership with Matakana Health (MHL) until early 2023, which will now include...
ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA)
December 02, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Dec. 02, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced that it has received approval from the Australian Therapeutic Goods Administration (TGA) for its patented...
European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food
November 20, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Nov. 20, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced that European Member States have voted in favor of listing Nicotinamide Riboside Chloride (NR) as a novel...
ChromaDex Corporation Reports Third Quarter 2019 Financial Results
November 12, 2019 16:01 ET
|
ChromaDex Corporation
Third Quarter 2019 Highlights vs. Third Quarter 2018 Strong growth in net sales to $12.1 million, improved gross margin, and significantly improved marketing efficiency year-over-year.TRU NIAGEN net...
ChromaDex to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
November 04, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Nov. 04, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Nov. 12, 2019 at 4:30 p.m. ET to discuss its financial results...
Tru Niagen® Wins ‘Most Favourite Brand’ Award Among Watsons Hong Kong Loyalty Members
October 31, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today its Tru Niagen® product was recognized as “MoneyBack Members’ Most Favourite Brand” at the Health,...
New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors
October 17, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Oct. 17, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of a preclinical study conducted by Nestlé were published last month in the journal...
ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation
October 11, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Oct. 11, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) issued the following statement. We would like to take this opportunity to comment on the latest order from the...
Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents
October 07, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda...